Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.

Smith CL, Jin Y, Raddad E, McNearney TA, Ni X, Monteith D, Brown R, Deeg MA, Schnitzer T.

Pharm Stat. 2019 Jan;18(1):39-53. doi: 10.1002/pst.1906. Epub 2018 Oct 15.

PMID:
30321909
2.

CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial.

Jin Y, Smith C, Monteith D, Brown R, Camporeale A, McNearney TA, Deeg MA, Raddad E, Xiao N, de la Peña A, Kivitz AJ, Schnitzer TJ.

Osteoarthritis Cartilage. 2018 Dec;26(12):1609-1618. doi: 10.1016/j.joca.2018.08.019. Epub 2018 Sep 18.

3.

Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist.

Guzman CB, Duvvuru S, Akkari A, Bhatnagar P, Battioui C, Foster W, Zhang XM, Shankar SS, Deeg MA, Chalasani N, Hardy TA, Kazda CM, Pillai SG.

Hepatol Commun. 2018 Mar 23;2(5):561-570. doi: 10.1002/hep4.1171. eCollection 2018 May.

4.

Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy After Single and Multiple Dosings of LY3016859 in Healthy Subjects and Patients With Diabetic Nephropathy.

Sloan-Lancaster J, Raddad E, Deeg MA, Eli M, Flynt A, Tumlin J.

Clin Pharmacol Drug Dev. 2018 Sep;7(7):759-772. doi: 10.1002/cpdd.436. Epub 2018 Jan 31.

PMID:
29385323
5.

Factors associated with stroke, myocardial infarction, ischemic heart disease, unstable angina, or mortality in patients from real world clinical practice with newly-diagnosed type 2 diabetes and early glycemic control.

Alatorre CI, Hoogwerf BJ, Deeg MA, Nelson DR, Hunter TM, Ng WT, Rekhter MD.

Curr Med Res Opin. 2018 Feb;34(2):337-343. doi: 10.1080/03007995.2017.1396969. Epub 2017 Nov 24.

PMID:
29065729
6.

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.

Kazda CM, Ding Y, Kelly RP, Garhyan P, Shi C, Lim CN, Fu H, Watson DE, Lewin AJ, Landschulz WH, Deeg MA, Moller DE, Hardy TA.

Diabetes Care. 2017 Jun;40(6):808. doi: 10.2337/dc17-er06. Epub 2017 Apr 18. No abstract available.

7.

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine.

Ilag LL, Costigan TM, Deeg MA, Pollom RK, Chang CL, Konrad RJ, Prince MJ.

Diabetes Ther. 2017 Jun;8(3):545-554. doi: 10.1007/s13300-017-0253-8. Epub 2017 Mar 30.

8.

Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.

Kazda CM, Ding Y, Kelly RP, Garhyan P, Shi C, Lim CN, Fu H, Watson DE, Lewin AJ, Landschulz WH, Deeg MA, Moller DE, Hardy TA.

Diabetes Care. 2016 Nov;39(11):e199-e200. No abstract available.

PMID:
27926898
9.

The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).

Hamdouchi C, Kahl SD, Patel Lewis A, Cardona GR, Zink RW, Chen K, Eessalu TE, Ficorilli JV, Marcelo MC, Otto KA, Wilbur KL, Lineswala JP, Piper JL, Coffey DS, Sweetana SA, Haas JV, Brooks DA, Pratt EJ, Belin RM, Deeg MA, Ma X, Cannady EA, Johnson JT, Yumibe NP, Chen Q, Maiti P, Montrose-Rafizadeh C, Chen Y, Reifel Miller A.

J Med Chem. 2016 Dec 22;59(24):10891-10916. doi: 10.1021/acs.jmedchem.6b00892. Epub 2016 Nov 11.

PMID:
27749056
10.

Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series.

Shankar SS, Vella A, Raymond RH, Staten MA, Calle RA, Bergman RN, Cao C, Chen D, Cobelli C, Dalla Man C, Deeg M, Dong JQ, Lee DS, Polidori D, Robertson RP, Ruetten H, Stefanovski D, Vassileva MT, Weir GC, Fryburg DA; Foundation for the National Institutes of Health β-Cell Project Team.

Diabetes Care. 2016 Sep;39(9):1602-13. doi: 10.2337/dc15-0931. Epub 2016 Jul 12.

11.

Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients.

Nicholls SJ, Ruotolo G, Brewer HB, Wang MD, Liu L, Willey MB, Deeg MA, Krueger KA, Nissen SE.

J Clin Lipidol. 2016 May-Jun;10(3):519-527.e4. doi: 10.1016/j.jacl.2015.11.014. Epub 2015 Dec 18.

PMID:
27206939
12.

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.

Kazda CM, Ding Y, Kelly RP, Garhyan P, Shi C, Lim CN, Fu H, Watson DE, Lewin AJ, Landschulz WH, Deeg MA, Moller DE, Hardy TA.

Diabetes Care. 2016 Jul;39(7):1241-9. doi: 10.2337/dc15-1643. Epub 2015 Dec 17. Erratum in: Diabetes Care. 2017 Jun;40(6):808.

PMID:
26681715
13.

Prognostic and predictive biomarkers of abdominal aortic aneurysm growth rate.

Deeg MA, Meijer CA, Chan LS, Shen L, Lindeman JH.

Curr Med Res Opin. 2016;32(3):509-17. doi: 10.1185/03007995.2015.1128406. Epub 2016 Jan 14.

PMID:
26636178
14.

Chemosensitization of Prostate Carcinoma Cells with a Receptor-directed Smac Conjugate.

Sturzu A, Sheikh S, Echner H, Deeg M, Nägele T, Weidenmaier C, Schwentner C, Horger M, Ernemann U, Heckl S.

Med Chem. 2016;12(5):412-8.

PMID:
26558373
15.

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.

Ilag LL, Deeg MA, Costigan T, Hollander P, Blevins TC, Edelman SV, Konrad RJ, Ortmann RA, Pollom RK, Huster WJ, Zielonka JS, Prince MJ.

Diabetes Obes Metab. 2016 Feb;18(2):159-68. doi: 10.1111/dom.12584. Epub 2016 Jan 8.

16.

Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes.

Kelly RP, Garhyan P, Raddad E, Fu H, Lim CN, Prince MJ, Pinaire JA, Loh MT, Deeg MA.

Diabetes Obes Metab. 2015 Apr;17(4):414-22. doi: 10.1111/dom.12446. Epub 2015 Mar 2.

PMID:
25656305
17.

[Automated audiometry - hearing tests with iOS based software suitable for "at home" tests?].

Deeg ME, Mlynski R.

Laryngorhinootologie. 2014 Sep;93(9):586-7. German. No abstract available.

PMID:
25298995
18.

Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects.

Payne CD, Deeg MA, Chan M, Tan LH, LaBell ES, Shen T, DeBrota DJ.

Br J Clin Pharmacol. 2014 Dec;78(6):1334-42. doi: 10.1111/bcp.12470.

19.

Physician preferences for extra-glycemic effects of type 2 diabetes treatments.

Poulos C, González JM, Lee LJ, Boye KS, Johnson FR, Bae JP, Deeg MA.

Diabetes Ther. 2013 Dec;4(2):443-59. doi: 10.1007/s13300-013-0046-7. Epub 2013 Nov 20.

20.

The gastrin/cholecystokinin-B receptor on prostate cells--a novel target for bifunctional prostate cancer imaging.

Sturzu A, Klose U, Sheikh S, Echner H, Kalbacher H, Deeg M, Nägele T, Schwentner C, Ernemann U, Heckl S.

Eur J Pharm Sci. 2014 Feb 14;52:69-76. doi: 10.1016/j.ejps.2013.10.013. Epub 2013 Nov 6.

PMID:
24211650
21.

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.

Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, Kharitonenkov A, Bumol T, Schilske HK, Moller DE.

Cell Metab. 2013 Sep 3;18(3):333-40. doi: 10.1016/j.cmet.2013.08.005.

22.

Homocysteine levels and dementia risk in Yoruba and African Americans.

Hendrie HC, Baiyewu O, Lane KA, Purnell C, Gao S, Hake A, Ogunniyi A, Gureje O, Unverzagt FW, Murrell J, Deeg MA, Hall K.

Int Psychogeriatr. 2013 Nov;25(11):1859-66. doi: 10.1017/S1041610213001294. Epub 2013 Jul 30.

23.

Rhodamine-marked bombesin: a novel means for prostate cancer fluorescence imaging.

Sturzu A, Sheikh S, Echner H, Nägele T, Deeg M, Amin B, Schwentner C, Horger M, Ernemann U, Heckl S.

Invest New Drugs. 2014 Feb;32(1):37-46. doi: 10.1007/s10637-013-9975-2. Epub 2013 Jun 1.

PMID:
23728918
24.

Ramoplanin imaging conjugates--synthesis and evaluation.

Sheikh S, Sturzu A, Kalbacher H, Klose U, Nagele T, Amin B, Deeg M, Horger M, Ernemann U, Heckl S.

Med Chem. 2014;10(1):18-26.

PMID:
23646874
25.

Novel bourgeonal fragrance conjugates for the detection of prostate cancer.

Sturzu A, Sheikh S, Echner H, Nägele T, Deeg M, Schwentner C, Horger M, Ernemann U, Heckl S.

Invest New Drugs. 2013 Oct;31(5):1151-7. doi: 10.1007/s10637-013-9943-x. Epub 2013 Mar 19.

PMID:
23508273
26.

A novel high-sensitivity electrochemiluminescence (ECL) sandwich immunoassay for the specific quantitative measurement of plasma glucagon.

Sloan JH, Siegel RW, Ivanova-Cox YT, Watson DE, Deeg MA, Konrad RJ.

Clin Biochem. 2012 Dec;45(18):1640-4. doi: 10.1016/j.clinbiochem.2012.07.111. Epub 2012 Aug 4.

PMID:
22890005
27.

Evaluating the diagnostic and chemotherapeutic potential of vancomycin-derived imaging conjugates.

Sheikh S, Sturzu A, Klose U, Echner H, Deeg M, Nägele T, Horger M, Schwentner C, Ernemann U, Voelter W, Heckl S.

Med Chem. 2012 Nov;8(6):1163-70.

PMID:
22741805
28.

Novel gastrin receptor-directed contrast agents - potential in brain tumor magnetic resonance imaging.

Sturzu A, Sheikh S, Klose U, Deeg M, Echner H, Nagele T, Ernemann U, Heckl S.

Med Chem. 2012 Mar;8(2):133-7.

PMID:
22385171
29.

Genetic variation of GPLD1 associates with serum GPI-PLD levels: a preliminary study.

Deeg MA, Xuei X, Eckert G, Considine RV, Li YG, Pratt JH.

Biochim Biophys Acta. 2012 Mar;1821(3):381-5. doi: 10.1016/j.bbalip.2011.12.009. Epub 2012 Jan 8.

PMID:
22260953
30.

Potential of the gastric motility drug lorglumide in prostate cancer imaging.

Sturzu A, Sheikh S, Klose U, Echner H, Kalbacher H, Deeg M, Nägele T, Horger M, Schwentner C, Ernemann U, Heckl S.

Eur J Pharm Sci. 2012 Apr 11;45(5):575-80. doi: 10.1016/j.ejps.2011.12.011. Epub 2011 Dec 30.

PMID:
22226647
31.

Using the neurotransmitter serotonin to target imaging agents to glioblastoma cells.

Sturzu A, Sheikh S, Klose U, Echner H, Kalbacher H, Deeg M, Nägele T, Horger M, Ernemann U, Heckl S.

Invest New Drugs. 2012 Dec;30(6):2141-7. doi: 10.1007/s10637-011-9780-8.

PMID:
22212740
32.

Dual-monoclonal, sandwich immunoassay specific for glucose-dependent insulinotropic peptide1-42, the active form of the incretin hormone.

Troutt JS, Siegel RW, Chen J, Sloan JH, Deeg MA, Cao G, Konrad RJ.

Clin Chem. 2011 Jun;57(6):849-55. doi: 10.1373/clinchem.2010.159954. Epub 2011 Apr 22.

33.

Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany.

Neilson AR, Sieper J, Deeg M.

Rheumatology (Oxford). 2010 Nov;49(11):2122-34. doi: 10.1093/rheumatology/keq222. Epub 2010 Jul 26.

PMID:
20660498
34.

Peptides derived from the human laminin alpha4 and alpha5 chains exhibit antimicrobial activity.

Senyürek I, Klein G, Kalbacher H, Deeg M, Schittek B.

Peptides. 2010 Aug;31(8):1468-72. doi: 10.1016/j.peptides.2010.04.016. Epub 2010 Apr 28.

PMID:
20433883
35.

Glycosylphosphatidylinositol-specific phospholipase D improves glucose tolerance.

Raikwar NS, Bowen-Deeg RF, Du XS, Low MG, Deeg MA.

Metabolism. 2010 Oct;59(10):1413-20. doi: 10.1016/j.metabol.2008.11.021. Epub 2010 Feb 11.

PMID:
20153004
36.

[Health-economic assessment of combination therapy for rheumatoid arthritis with methotrexat and etanercept based on the TEMPO Study].

Schulze-Koops H, Deeg M, Runge C, Volmer T, Brecht JG.

Z Rheumatol. 2009 Dec;68(10):836-41. doi: 10.1007/s00393-009-0506-7. German.

PMID:
19756664
37.

Dermcidin-derived peptides show a different mode of action than the cathelicidin LL-37 against Staphylococcus aureus.

Senyürek I, Paulmann M, Sinnberg T, Kalbacher H, Deeg M, Gutsmann T, Hermes M, Kohler T, Götz F, Wolz C, Peschel A, Schittek B.

Antimicrob Agents Chemother. 2009 Jun;53(6):2499-509. doi: 10.1128/AAC.01679-08. Epub 2009 Apr 13.

38.

Resistance to dermcidin-derived peptides is independent of bacterial protease activity.

Senyürek I, Döring G, Kalbacher H, Deeg M, Peschel A, Wolz C, Schittek B.

Int J Antimicrob Agents. 2009 Jul;34(1):86-90. doi: 10.1016/j.ijantimicag.2008.12.008. Epub 2009 Feb 7.

PMID:
19201578
39.

A comparison of cardiovascular disease risk factor biomarkers in African Americans and Yoruba Nigerians.

Deeg M, Baiyewu O, Gao S, Ogunniyi A, Shen J, Gureje O, Taylor S, Murrell J, Unverzagt F, Smith-Gamble V, Evans R, Dickens J, Hendrie H, Hall K.

Ethn Dis. 2008 Autumn;18(4):427-33.

41.
42.

Association of statin use with cognitive decline in elderly African Americans.

Szwast SJ, Hendrie HC, Lane KA, Gao S, Taylor SE, Unverzagt F, Murrell J, Deeg M, Ogunniyi A, Farlow MR, Hall KS.

Neurology. 2007 Nov 6;69(19):1873-80.

43.

Heterologous expression of Mytilus californianus foot protein three (Mcfp-3) in Kluyveromyces lactis.

Platko JD, Deeg M, Thompson V, Al-Hinai Z, Glick H, Pontius K, Colussi P, Taron C, Kaplan DL.

Protein Expr Purif. 2008 Jan;57(1):57-62. Epub 2007 Sep 5.

PMID:
17923416
44.

Development of progressive aortic vasculopathy in a rat model of aging.

Miller SJ, Watson WC, Kerr KA, Labarrere CA, Chen NX, Deeg MA, Unthank JL.

Am J Physiol Heart Circ Physiol. 2007 Nov;293(5):H2634-43. Epub 2007 Sep 14.

45.

Statin therapy reduces serum levels of glycosylphosphatidylinositol-specific phospholipase D.

Deeg MA, Raikwar NS, Johnson C, Williams CD.

Transl Res. 2007 Sep;150(3):153-7. Epub 2007 May 25.

PMID:
17761367
46.

Primary care physician treatment of low HDL: Rational approach or Pandora's Box?

Deeg MA, Jacob S, Shen J, Marrero DG.

J Clin Lipidol. 2007 Jul;1(3):198-202. doi: 10.1016/j.jacl.2007.04.002. Epub 2007 Apr 20.

PMID:
21291682
47.

Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia.

Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, Khan MA, Perez AT, Tan MH; GLAI Study Investigators.

Diabetes Care. 2007 Oct;30(10):2458-64. Epub 2007 Jun 26.

PMID:
17595355
48.

Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148.

Dubé MP, Wu JW, Aberg JA, Deeg MA, Alston-Smith BL, McGovern ME, Lee D, Shriver SL, Martinez AI, Greenwald M, Stein JH; AIDS Clinical Trials Group A5148 Study Team.

Antivir Ther. 2006;11(8):1081-9.

49.

Naturally processed dermcidin-derived peptides do not permeabilize bacterial membranes and kill microorganisms irrespective of their charge.

Steffen H, Rieg S, Wiedemann I, Kalbacher H, Deeg M, Sahl HG, Peschel A, Götz F, Garbe C, Schittek B.

Antimicrob Agents Chemother. 2006 Aug;50(8):2608-20.

50.

Renal injury: similarities and differences in male and female rats with the metabolic syndrome.

Dominguez JH, Wu P, Hawes JW, Deeg M, Walsh J, Packer SC, Nagase M, Temm C, Goss E, Peterson R.

Kidney Int. 2006 Jun;69(11):1969-76.

Supplemental Content

Support Center